SEL-120

Ryvu's RVU305, a brain-permeable MTA-cooperative PRMT5 inhibitor, demonstrates significant tumor growth inhibition in MTAP-deleted cancer models and enhances responses when combined with anti-PD-1 antibodies.

Ryvu Therapeutics has dosed the first patient in the JASPIS-01 Phase II trial evaluating dapolsertib as both monotherapy and in combination with glofitamab for relapsed/refractory diffuse large B-cell lymphoma.

Ryvu Therapeutics announces strategic reorganization, reducing workforce by 30% while extending cash runway to H2 2026 with €46 million in current assets and €22 million in secured grant funding.

Ryvu Therapeutics has successfully launched four Phase II clinical studies (RIVER-52, RIVER-81, POTAMI-61, and REMARK) for RVU120, with key efficacy analyses expected in H1 2025.

Ryvu Therapeutics has dosed the first patient in the Phase II POTAMI-61 trial evaluating RVU120 for myelofibrosis (MF).